Results 211 to 220 of about 105,631 (265)

Therapeutic drug monitoring of ceftazidime/avibactam: why one leg is not enough to run.

Journal of Antimicrobial Chemotherapy, 2023
BACKGROUND Therapeutic drug monitoring (TDM) is becoming an increasingly recommended approach for assessing optimal pharmacokinetic/pharmacodynamic (PK/PD) target attainment of ceftazidime/avibactam.
Milo Gatti, P. Viale, F. Pea
semanticscholar   +1 more source

Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.

Journal of Antimicrobial Chemotherapy, 2022
OBJECTIVES To evaluate the activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against a clinical and laboratory collection of ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa β ...
Cristina Lasarte-Monterrubio, P. Fraile-Ribot, J. C. Vázquez-Ucha, G. Cabot, Paula Guijarro-Sánchez, Isaac Alonso-García, S. Rumbo-Feal, F. Galán-Sánchez, A. Beceiro, J. Arca-Suárez, A. Oliver, G. Bou   +11 more
semanticscholar   +1 more source

Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales.

Clinical Infectious Diseases, 2020
BACKGROUND In vitro data support the use of combination of aztreonam (ATM) with ceftazidime-avibactam (CAZ-AVI), but clinical studies are lacking. The aim of our study was to compare the outcome of patients with bloodstream infections (BSIs) due to MBLs ...
M. Falcone, G. Daikos, G. Tiseo, D. Bassoulis, Cesira Giordano, V. Galfo, A. Leonildi, E. Tagliaferri, S. Barnini, S. Sani, A. Farcomeni, L. Ghiadoni, F. Menichetti   +12 more
semanticscholar   +1 more source

Ceftazidime Review

Drug Intelligence & Clinical Pharmacy, 1985
The chemistry, in vitro activity, adverse effects, and clinical indications for the new third-generation cephalosporin, ceftazidime, are reviewed. Ceftazidime appears to have a unique place among the third-generation agents in the treatment of some infectious processes caused by Pseudomonas aeruginosa.
Richard L. Yost, Reuben Ramphal, Donald C. McLeod   +2 more
openaire   +2 more sources

Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study.

Lancet. Infectious Diseases (Print)
BACKGROUND Ceftolozane-tazobactam and ceftazidime-avibactam are preferred treatment options for multidrug-resistant Pseudomonas aeruginosa infections; however, real-world comparative effectiveness studies are scarce.
R. K. Shields, Lilian M. Abbo, Renee Ackley, Samuel L. Aitken, Benjamin Albrecht, Ahmed Babiker, R. Burgoon, Renzo Cifuentes, K. Claeys, Brooke N Curry, Kathryn DeSear, Jason C Gallagher, Esther Y. Golnabi, Alan E. Gross, Jonathan Hand, Emily L Heil, K. Hornback, Keith S Kaye, Trieu-Vi Khuu, Megan E Klatt, Ellen G. Kline, Ryan C. Kubat, W. Kufel, Jae Hyoung Lee, A. Lepak, Ahmi Lim, Justin Ludwig, C. MacDougall, Anjali Majumdar, Amy J Mathers, E. McCreary, William R Miller, M. Monogue, W. Moore, Shannon Olson, Jessica Oxer, J. Pearson, Christine Pham, Paulette Pinargote, C. Polk, M. Satlin, S. Satola, Sunish Shah, P. Tamma, T. Tran, D. van Duin, M. VanNatta, Ana Vega, V. Venugopalan, M. Veve, W. Wangchinda, Lucy S Witt, Janet Y. Wu, J. Pogue   +53 more
semanticscholar   +1 more source

Dynamic interaction between lysozyme and ceftazidime: Experimental and molecular simulation approaches

, 2021
The interaction of an important antibiotic drug, ceftazidime, with an imperative globular protein, lysozyme (which also possesses antibacterial properties), was studied.
Mohd. Sajid Ali, M. Waseem, N. Subbarao, H. Al‐Lohedan   +3 more
semanticscholar   +1 more source